TLN 232

Drug Profile

TLN 232

Alternative Names: CAP-232; TLN-232; TT-232

Latest Information Update: 19 Aug 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biostatin Research and Development Ltd
  • Developer BELLUS Health
  • Class Antineoplastics; Cyclic peptides
  • Mechanism of Action Pyruvate kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Malignant melanoma; Pancreatic cancer; Renal cancer

Most Recent Events

  • 15 Aug 2013 Thallion Pharmaceuticals has been acquired and merged into BELLUS Health
  • 23 Jun 2010 Thallion Pharmaceuticals discontinues its development programme for TLN 232
  • 17 Jun 2010 Discontinued - Phase-II for Malignant melanoma in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top